Table 1.
Characteristic | All | Surgeon 1 | Surgeon 2 | Surgeon 3 | p value |
---|---|---|---|---|---|
Patients, n | 594 | 181 | 275 | 138 | − |
Patient age, mean (SD), years | 70.9 (8.4) | 71.2 (8.2) | 71.1 (8.4) | 69.8 (8.7) | 0.204 |
ASA score, n (%) | |||||
I | 41 (6.9) | 17 (9.4) | 15 (5.5) | 9 (6.5) | 0.411 |
II | 333 (56.1) | 98 (54.1) | 157 (57.1) | 78 (56.5) | |
III | 212 (35.7) | 64 (35.4) | 97 (35.3) | 51 (37.0) | |
IV | 8 (1.3) | 2 (1.1) | 6 (2.2) | 0 (0) | |
Preoperative indwelling catheter, n (%) | |||||
None | 389 (65.5) | 117 (64.6) | 180 (65.5) | 92 (66.7) | 0.825 |
Transurethral | 169 (28.5) | 50 (27.6) | 81 (29.5) | 38 (27.5) | |
Suprapubic | 36 (6.0) | 14 (7.7) | 14 (5.1) | 8 (5.8) | |
Preoperative UTI, n (%) | |||||
Yes | 202 (34.0) | 71 (39.2) | 94 (34.2) | 37 (26.8) | 0.068 |
No | 392 (66.0) | 110 (60.8) | 181 (65.8) | 101 (73.2) | |
Anticoagulation/antiplatelet Tx, n (%) | |||||
Yes | 222 (37.4) | 62 (34.3) | 109 (39.6) | 51 (37.0) | 0.506 |
No | 372 (62.6) | 119 (65.7) | 166 (60.4) | 87 (63.0) | |
Preoperative prostate volume, median (IQR), cc | 85.0 (44.0) | 93.0 (43.0) | 80.0 (45.0) | 75.0 (40.0) | <0.001 |
Preoperative total PSA, median (IQR), ng/mL | 4.86 (5.84) | 5.31 (5.50) | 4.73 (5.62) | 4.22 (6.80) | 0.212 |
Any previous prostate biopsy, n (%) | |||||
Yes | 164 (27.6) | 47 (26.0) | 75 (27.3) | 42 (30.4) | 0.667 |
No | 430 (72.4) | 134 (74.0) | 200 (72.7) | 96 (69.6) | |
Prostate biopsy within 8 weeks before HoLEP, n (%) | |||||
Yes | 61 (10.3) | 19 (10.5) | 28 (10.2) | 14 (10.1) | 0.993 |
No | 533 (89.7) | 162 (89.5) | 247 (89.8) | 124 (89.9) | |
Preoperative known prostate cancer, n (%) | |||||
Yes | 25 (4.2) | 4 (2.2) | 6 (2.2) | 15 (10.9) | <0.001 |
No | 569 (95.8) | 177 (97.8) | 269 (97.8) | 123 (89.1) |
Bold values indicate p values <0.05. UTI, urinary tract infection; Tx, therapy; PSA, prostate-specific antigen; HoLEP, holmium laser enucleation of the prostate; ASA, American Society of Anesthesiologists.